Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
384
Recruiting Now
384
Top Conditions in Phase 1 / Phase 2
Frequently Asked Questions — Phase 1 / Phase 2 Trials
What are combined Phase 1/2 clinical trials?
Phase 1/2 trials are adaptive designs that evaluate both safety (Phase 1 objectives) and preliminary efficacy (Phase 2 objectives) within a single trial protocol. They are commonly used in oncology and rare disease research to accelerate development timelines. Dose escalation occurs in the Phase 1 portion, followed by expansion cohorts at the selected dose in the Phase 2 portion.
Why do sponsors combine Phase 1 and Phase 2?
Combining phases reduces development time and cost, particularly for conditions with high unmet need. For rare diseases or cancer indications, finding sufficient eligible patients can be challenging—a combined design uses the same patient pool more efficiently. Regulatory agencies including the FDA encourage adaptive designs to accelerate evidence generation for serious conditions.
How do I find Phase 1/2 trials I can join?
Phase 1/2 trials listed on ClinicalMetric are sourced from ClinicalTrials.gov and filtered by recruitment status. Each listing shows enrollment status, conditions studied, sponsor, participating sites, and estimated enrollment. Because Phase 1/2 trials often have narrow eligibility criteria, carefully review the protocol and discuss potential participation with your treating physician.
Active Phase 1 / Phase 2 Studies
NCT07698106 Phase 1, Phase 2
Recruiting
Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC
Condition
Triple-Negative Breast Cancer (TNBC)
Enrollment
60 pts
Location
Canada
Sponsor
University Health Network, Tor
NCT06639347 Phase 1, Phase 2
Recruiting
A Trial of SHR-A2102 With Antitumor Therapy in Advanced Urothelial Carcinoma
Condition
Advanced Urothelial Carcinoma
Enrollment
90 pts
Location
China
Sponsor
Shanghai Hengrui Pharmaceutica
NCT06753747 Phase 1, Phase 2
Recruiting
A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Adv...
Condition
Esophagus Cancer
Enrollment
45 pts
Location
China
Sponsor
West China Hospital
NCT06425926 Phase 1, Phase 2
Recruiting
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
Condition
Melanoma Stage IV
Enrollment
117 pts
Location
United States
Sponsor
Georgiamune Inc
NCT05747261 Phase 1, Phase 2
Recruiting
Study of the Safety and Efficacy of an Adeno-Associated Viral Vector Carrying th...
Condition
Spinal Muscular Atrophy (SMA)
Enrollment
40 pts
Location
Belarus, Russia
Sponsor
Biocad
NCT07110584 Phase 1, Phase 2
Recruiting
Dose Escalation and Dose Expansion Study of MDX2004 in Participants With Advance...
Condition
Advanced Tumors
Enrollment
235 pts
Location
Australia, Israel
Sponsor
ModeX Therapeutics, An OPKO He
NCT07539155 Phase 1, Phase 2
Recruiting
Intratumoral MMR Vaccine Injection in Borderline Resectable/Unresectable Pancrea...
Condition
Borderline Resectable/Unresectable Pancreatic Cancer
Enrollment
20 pts
Location
United States
Sponsor
University of Arkansas
NCT06270316 Phase 1, Phase 2
Recruiting
Safety, PK/PD, and Exploratory Efficacy Study of AMT-191 in Classic Fabry Diseas...
Condition
Fabry Disease
Enrollment
20 pts
Location
United States
Sponsor
UniQure Biopharma B.V.
NCT06430385 Phase 1, Phase 2
Recruiting
ATTUNE: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Phar...
Condition
Methyl CpG Binding Protein 2 (MECP2) Duplication Syndrome
Enrollment
48 pts
Location
United States, Austria, Canada
Sponsor
Ionis Pharmaceuticals, Inc.
NCT07396155 Phase 1, Phase 2
Recruiting
Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy i...
Condition
Diabetic Nephropathy Type 2
Enrollment
10 pts
Location
Indonesia
Sponsor
PT. Prodia Stem Cell Indonesia
NCT04864054 Phase 1, Phase 2
Recruiting
GPC3-Targeted T-Cell Therapy (ECT204) in Adults With Advanced HCC
Condition
Hepatocellular Carcinoma
Enrollment
60 pts
Location
United States, Taiwan
Sponsor
Eureka Therapeutics Inc.
NCT05588141 Phase 1, Phase 2
Recruiting
000860: A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With ...
Condition
Brain Tumor
Enrollment
96 pts
Location
United States
Sponsor
National Cancer Institute (NCI
NCT07359066 Phase 1, Phase 2
Recruiting
An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Stu...
Condition
Advanced Solid Tumors
Enrollment
210 pts
Location
China
Sponsor
Shanghai SciBrunch Therapeutic
NCT02259556 Phase 1, Phase 2
Recruiting
CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refra...
Condition
Hodgkin's Lymphoma
Enrollment
30 pts
Location
China
Sponsor
Chinese PLA General Hospital
NCT06836505 Phase 1, Phase 2
Recruiting
Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma ...
Condition
Neuroblastoma (NB)
Enrollment
10 pts
Location
China
Sponsor
Sun Yat-Sen University Cancer
NCT04625907 Phase 1, Phase 2
Recruiting
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapse...
Condition
Rhabdomyosarcoma
Enrollment
1,672 pts
Location
Australia, Austria, Belgium
Sponsor
University of Birmingham
NCT07096934 Phase 1, Phase 2
Recruiting
Controlled Trial to Evaluate the Safety and Efficacy of CYWC628 (Human Dermal Fi...
Condition
Diabetic Foot Ulcer (DFU)
Enrollment
120 pts
Location
Australia
Sponsor
FibroBiologics
NCT07549698 Phase 1, Phase 2
Recruiting
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Re...
Condition
Warm Autoimmune Hemolytic Anemia (WAIHA)
Enrollment
60 pts
Location
United States, Germany, Spain
Sponsor
CRISPR Therapeutics AG
NCT07056777 Phase 1, Phase 2
Recruiting
Evaluation of the Preliminary Efficacy and Safety of DR30206 in Combination With...
Condition
Gastrointestinal Cancer
Enrollment
186 pts
Location
China
Sponsor
Zhejiang Doer Biologics Co., L
NCT04300556 Phase 1, Phase 2
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein ...
Condition
Solid Tumor
Enrollment
182 pts
Location
United States, France, Japan
Sponsor
Eisai Inc.
NCT07481422 Phase 1, Phase 2
Recruiting
Safety and Efficacy of Lyophilized Faecal Microbiota Transplantation Via Capsule...
Condition
Irritable Bowel Syndrome (IBS)
Enrollment
70 pts
Location
Croatia
Sponsor
University of Rijeka
NCT07050641 Phase 1, Phase 2
Recruiting
Phase I/II Study of SCTB39-1 in Advanced Solid Tumours
Condition
Advanced Malignant Solid Tumor
Enrollment
110 pts
Location
China
Sponsor
Sinocelltech Ltd.
NCT07682870 Phase 1, Phase 2
Recruiting
A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pre...
Condition
Advanced Malignant Solid Tumor
Enrollment
42 pts
Location
China
Sponsor
Virogin Biotech Ltd.
NCT06650566 Phase 1, Phase 2
Recruiting
Study of LM-299 in Subjects Advanced Malignant Tumors
Condition
Malignant Tumors
Enrollment
108 pts
Location
Australia, China
Sponsor
LaNova Medicines Limited
NCT06675422 Phase 1, Phase 2
Recruiting
JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)
Condition
Systemic Lupus Erythematosus (SLE)
Enrollment
20 pts
Location
China
Sponsor
920th Hospital of Joint Logist
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology